MAGEC2 and hepatocellular carcinoma: Previous studies showed that MAGE-C2 was expressed most frequently in patients with hepatocellular carcinoma and non-small cell lung cancer but not expressed in the corresponding adjacent healthy tissue samples [33,34], which suggests that they could be used as a cancer biomarker.